Other treatment Cancer Narrative 22044-2
LOINC Code
LOINC code | 22044-2 | ||||
---|---|---|---|---|---|
name | Other treatment Cancer Narrative | ||||
description | Text area for manual documentation of information regarding the treatment of the tumor being reported with treatment that cannot be defined as surgery, radiation, or systemic therapy. This includes experimental treatments (when the mechanism of action for a drug is unknown), and blinded clinical trials. If the mechanism of action for the experimental drug is known, code to the appropriate treatment field... NAACCR Data Standards and Data Dictionary Version 11 | ||||
status | ACTIVE | ||||
Fully-Specified Name | |||||
component | Other Rx | ||||
property | Find = Finding | ||||
time | Pt = Point in time: To identify measures at a point in time. This is a synonym for “spot” or “random” as applied to urine measurements. | ||||
system | Cancer.XXX | ||||
scale | Nar = Narrative: Text narrative, such as the description of a microscopic part of a surgical papule test. | ||||
method | |||||
Additional Names | |||||
short name | Other Rx Cancer | ||||
Basic Attributes | |||||
class | TUMRRGT | ||||
type | 2 Clinical | ||||
Associated Observations | |||||
LOINC codes that represent optional associated observation(s) for a clinical observation or laboratory test. A LOINC term may represent a single associated observation or panel containing several associated observations. | |||||
Member of these Panels | |||||
| |||||
History/Usage | |||||
first released | |||||
last updated | 2.40 | ||||
last change type | MIN - change to field other than name | ||||
Related Names | |||||
|
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.
Thank you for choosing Find-A-Code, please Sign In to remove ads.